RESUMEN
Human papillomaviruses (HPV)-related gynecological cancers are a major health care issue, and a leading cause of cancer death in low- and middle-income countries (LMIC). In 2020, the World Health Organization launched a program aimed at cervical cancer elimination, by screening and vaccination strategies. Offering the best possible care to women diagnosed with invasive cancer is a complementary objective. Treatment of cervical cancer as per modern standards is complex and multimodal, mainly relying on surgery, external-beam radiotherapy (+/-chemotherapy) and brachytherapy. In parallel with the pivotal role of multidisciplinary discussion, international societies provide guidance to define the most effective and least toxic anti-cancer strategy, homogenize treatment protocols and provide benchmark quality indicators as a basis for accreditation processes. The challenge is to offer the appropriate diagnostic workup and treatment upfront and to avoid non- evidence-based treatment that consumes resources, impairs quality of life (QoL), and compromises oncological outcome. Various strategies may be applied for improving treatment quality: development of surgical mentorship, companion-training programs and international cooperation. The lack of radiotherapy/brachytherapy facilities is a major concern in LMIC. Reinforcing international support in terms of education, training, research and development and technical cooperation with national projects is required to increase access to minimum requirements but also introduce modern techniques, upgrade radiotherapy/brachytherapy services, and expand access to modern systemic treatments. In countries with robust economies, compliance to standards should also be increased. Integrative cancer care and multidisciplinary approaches are needed to tackle the dual challenge of increasing cure rates while minimizing QoL impairment. Appropriate dimensioning of the resources to avoid harmful treatment delays and access to expert referral centers is also a priority.
Asunto(s)
Accesibilidad a los Servicios de Salud , Infecciones por Papillomavirus/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Braquiterapia , Femenino , Salud Global , Humanos , Tamizaje Masivo , Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/radioterapia , Neoplasias del Cuello Uterino/prevención & control , Neoplasias del Cuello Uterino/radioterapia , VacunaciónRESUMEN
Prophylactic human papillomavirus (HPV) vaccines are commercially available for prevention of infection with cancerogenic HPV genotypes but are not able to combat pre-existing HPV-associated disease. In this study, we designed a nanomaterial-based therapeutic HPV vaccine, comprising manganese (Mn4+)-doped silica nanoparticles (Mn4+-SNPs) and the viral neoantigen peptide GF001 derived from the HPV16 E7 oncoprotein. We show in mice that Mn4+-SNPs act as self-adjuvants by activating the inflammatory signaling pathway via generation of reactive oxygen species, resulting in immune cell recruitment to the immunization site and dendritic cell maturation. Mn4+-SNPs further serve as Ag carriers by facilitating endo/lysosomal escape via depletion of protons in acidic endocytic compartments and subsequent Ag delivery to the cytosol for cross-presentation. The Mn4+-SNPs+GF001 nanovaccine induced strong E7-specific CD8+ T cell responses, leading to remission of established murine HPV16 E7-expressing solid TC-1 tumors and E7-expressing transgenic skin grafts. This vaccine construct offers a simple and general strategy for therapeutic HPV and potentially other cancer vaccines.
Asunto(s)
Antígenos de Neoplasias/inmunología , Manganeso/inmunología , Nanopartículas/administración & dosificación , Neoplasias/inmunología , Neoplasias/terapia , Dióxido de Silicio/inmunología , Adyuvantes Inmunológicos/farmacología , Animales , Linfocitos T CD8-positivos/inmunología , Vacunas contra el Cáncer/inmunología , Células Cultivadas , Femenino , Humanos , Inmunización/métodos , Inmunoterapia/métodos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Papillomaviridae/inmunología , Proteínas E7 de Papillomavirus/inmunología , Infecciones por Papillomavirus/inmunología , Vacunas contra Papillomavirus/inmunología , Polimorfismo de Nucleótido Simple/inmunología , Especies Reactivas de Oxígeno/inmunología , Transducción de Señal/inmunologíaRESUMEN
Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle in vaccine development. Over 200 distinct genomic sequences have been identified for human papillomavirus (HPV), of which more than 18 are associated with cervical cancer. Here, based on the high structural similarity of L1 surface loops within a group of phylogenetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric protein recapitulates the conformational contours of the antigenic surfaces of the parental-type proteins, offering a basis for this high immunity. Our stratagem is equally successful in developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70, HPV18/45/59), paving the way for the development of an improved HPV prophylactic vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to other microbes.
Asunto(s)
Diseño de Fármacos , Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/inmunología , Neoplasias del Cuello Uterino/prevención & control , Animales , Anticuerpos Antivirales/genética , Anticuerpos Antivirales/inmunología , Proteínas de la Cápside/genética , Proteínas de la Cápside/inmunología , Evaluación Preclínica de Medicamentos , Epítopos/genética , Epítopos/inmunología , Femenino , Ingeniería Genética/métodos , Inmunogenicidad Vacunal , Macaca fascicularis , Masculino , Ratones , Ratones Endogámicos BALB C , Modelos Animales , Pruebas de Neutralización , Proteínas Oncogénicas Virales/genética , Proteínas Oncogénicas Virales/inmunología , Papillomaviridae/genética , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/genética , Filogenia , Organismos Libres de Patógenos Específicos , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/virologíaRESUMEN
Human papilloma virus (HPV)-associated cancer is a significant global health burden and despite the presence of viral transforming antigens within neoplastic cells, therapeutic vaccinations are ineffective for advanced disease. HPV positive TC1 cells are susceptible to viral oncolysis by MG1-E6E7, a custom designed oncolytic Maraba virus. Epitope mapping of mice vaccinated with MG1-E6E7 enabled the rational design of synthetic long peptide (SLP) vaccines against HPV16 and HPV18 antigens. SLPs were able to induce specific CD8+ immune responses and the magnitude of these responses significantly increased when boosted by MG1-E6E7. Logically designed vaccination induced multi-functional CD8+ T cells and provided complete sterilising immunity of mice challenged with TC1 cells. In mice bearing large HPV-positive tumours, SLP vaccination combined with MG1-E6E7 was able to clear tumours in 60% of mice and these mice were completely protected against a long term aggressive re-challenge with the TC1 tumour model. Combining conventional SLPs with the multi-functional oncolytic MG1-E6E7 represents a promising approach against advanced HPV positive neoplasia.
Asunto(s)
Vacunas contra el Cáncer/inmunología , Inmunoterapia , Neoplasias/etiología , Neoplasias/terapia , Viroterapia Oncolítica , Virus Oncolíticos/genética , Infecciones por Papillomavirus/complicaciones , Vacunas de Subunidad/inmunología , Secuencia de Aminoácidos , Animales , Antígenos Virales/inmunología , Vacunas contra el Cáncer/administración & dosificación , Línea Celular , Terapia Combinada , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Mapeo Epitopo , Epítopos/inmunología , Femenino , Humanos , Inmunización , Ratones , Neoplasias/patología , Viroterapia Oncolítica/métodos , Papillomaviridae/inmunología , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/virología , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/química , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Animal models have played a pivotal role in all stages of vaccine development. Their predictive value for vaccine effectiveness depends on the pathogen, the robustness of the animal challenge model, and the correlates of protection (if known). This article will cover key questions regarding bridging animal studies to efficacy trials in humans. Examples include human papillomavirus (HPV) vaccine in which animal protection after vaccination with heterologous prototype virus-like particles (VLPs) predicted successful efficacy trials in humans, and a recent approval of anthrax vaccine in accordance with the "Animal Rule." The establishment of animal models predictive of vaccine effectiveness in humans has been fraught with difficulties with low success rate to date. Challenges facing the use of animal models for vaccine development against Ebola and HIV will be discussed.
Asunto(s)
Modelos Animales de Enfermedad , Vacunas/uso terapéutico , Vacunas contra el SIDA/efectos adversos , Vacunas contra el SIDA/uso terapéutico , Animales , Carbunco/inmunología , Vacunas contra el Carbunco/efectos adversos , Vacunas contra el Carbunco/uso terapéutico , Aprobación de Drogas , Evaluación Preclínica de Medicamentos , Vacunas contra el Virus del Ébola/efectos adversos , Vacunas contra el Virus del Ébola/uso terapéutico , Humanos , Papillomaviridae/inmunología , Vacunas contra Papillomavirus/efectos adversos , Vacunas contra Papillomavirus/uso terapéutico , Prueba de Estudio Conceptual , Especificidad de la EspecieRESUMEN
Patients receiving tumour necrosis factor alpha (TNF-α) inhibitors are at increased risk of exacerbation of (myco-)bacterial and some viral infections. However, information on anogenital human papillomavirus (HPV) infection in these patients is sparse or conflicting. In this study 222 patients with psoriasis or inflammatory bowel disease (IBD), who received either anti-TNF-α inhibitors or alternatives (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) continuously for at least 6 months, were evaluated for the presence of anogenital HPV-induced lesions, mucosal HPV DNA, and serological status of mucosal low-risk HPV6 and high-risk HPV16/HPV18. Hallmarks of anogenital HPV infection were more frequently detected in patients with psoriasis than in those with IBD. HPV-induced lesions, viral DNA, and seroprevalence were not elevated in participants with psoriasis or IBD, who received TNF-α inhibitors for a mean duration of 31.4 months (range 6-96 months) compared with recipients of alternative or no treatment. TNF-α blockade for a mean period of 31.4 months does not increase detectable anogenital HPV infection or disease.
Asunto(s)
Antiinflamatorios/uso terapéutico , Enfermedades del Ano/epidemiología , Condiloma Acuminado/epidemiología , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Infecciones por Papillomavirus/epidemiología , Psoriasis/tratamiento farmacológico , Infecciones del Sistema Genital/epidemiología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Anciano , Antiinflamatorios/efectos adversos , Enfermedades del Ano/diagnóstico , Enfermedades del Ano/inmunología , Enfermedades del Ano/virología , Austria/epidemiología , Condiloma Acuminado/diagnóstico , Condiloma Acuminado/inmunología , Condiloma Acuminado/virología , Femenino , Humanos , Huésped Inmunocomprometido , Enfermedades Inflamatorias del Intestino/diagnóstico , Enfermedades Inflamatorias del Intestino/epidemiología , Enfermedades Inflamatorias del Intestino/inmunología , Masculino , Persona de Mediana Edad , Papillomaviridae/inmunología , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/virología , Prevalencia , Estudios Prospectivos , Psoriasis/diagnóstico , Psoriasis/epidemiología , Psoriasis/inmunología , Infecciones del Sistema Genital/diagnóstico , Infecciones del Sistema Genital/inmunología , Infecciones del Sistema Genital/virología , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Factor de Necrosis Tumoral alfa/inmunología , Adulto JovenRESUMEN
PURPOSE: How tumors evade or suppress immune surveillance is a key question in cancer research, and overcoming immune escape is a major goal for lengthening remission after cancer treatment. Here, we used the papillomavirus-associated rabbit auricular VX2 carcinoma, a model for studying human head and neck cancer, to reveal the mechanisms underlying the antitumorigenic effects of intraperitoneal oxidative stress following O3/O2-pneumoperitoneum (O3/O2-PP) treatment. EXPERIMENTAL DESIGN: Solid auricular VX2 tumors were induced in immune-competent adult New Zealand White Rabbits. Animals were O3/O2-PP- or sham-treated, after which they underwent tumor ablation upon reaching no-go criteria. CD3(+) tumor-infiltrating lymphocytes (TIL) were evaluated by immunohistochemistry, and expression levels of 84 immune response genes were measured by quantitative real-time PCR. Adoptive transfer of peripheral blood leukocytes (PBL)-derived from animals with tumor regression-into control animals with progressing tumors was implemented to assess acquired tumor resistance functionally. RESULTS: Auricular VX2 tumors regressing after O3/O2-PP treatment exhibited increased levels of CD3(+) TILs; they also exhibited enhanced expression of genes that encode receptors involved in pattern recognition, molecules that are required for antigen presentation and T cell activation, and inflammatory mediators. Adoptive cell transfer of PBLs from donor rabbits with regressing tumors to recipient rabbits with newly implanted VX2 carcinoma resulted in acquired tumor resistance of the host and tumor regression. CONCLUSION: Intraperitoneal oxidative stress effectively converts the immune response against the papillomavirus-associated rabbit VX2 carcinoma from tumor permissive to tumoricidal and leads to a sustainable, adoptively transferable oncolytic immune response.
Asunto(s)
Neoplasias de Cabeza y Cuello/prevención & control , Neoplasias Pulmonares/prevención & control , Linfocitos Infiltrantes de Tumor/inmunología , Estrés Oxidativo , Oxígeno/uso terapéutico , Ozono/uso terapéutico , Papillomaviridae/inmunología , Traslado Adoptivo , Animales , Carcinoma de Células Escamosas/inmunología , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/prevención & control , Neoplasias de Cabeza y Cuello/inmunología , Neoplasias de Cabeza y Cuello/metabolismo , Humanos , Técnicas para Inmunoenzimas , Inmunoterapia Adoptiva , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/secundario , Activación de Linfocitos , Masculino , Neumoperitoneo/inmunología , ARN Mensajero/genética , Conejos , Reacción en Cadena en Tiempo Real de la Polimerasa , Inducción de Remisión , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales CultivadasRESUMEN
BACKGROUND: Information on genital wart incidence in adolescents and young adults before human papillomavirus (HPV) vaccination is important for understanding the impact of the vaccine on the epidemiology of this early outcome of HPV infection. METHODS: The study population included 11- to 29-year-old enrollees of Northern California Kaiser Permanente between July 1, 2000, and July 1, 2005, before the availability of the HPV vaccine. We identified genital warts with an algorithm combining genital wart-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes (078.10, 078.11, and 078.19) with physician-recorded anatomic locations. We calculated sex- and age-specific incidence rates of genital warts and described the specific anatomic location of presentation, as well as recurrences of genital warts. RESULTS: We identified 1,682 cases of genital warts among 181,264 individuals. The incidence rate was highest among women (6.3/1000 person-years) and men (2.9/1000 person-years) aged 20 to 24 years old. Among women (n = 96,792), 63.4% of the 1240 incident genital wart cases occurred on the vulva and 21.1% on the cervix. Among men (n = 84,472), 91.6% of the 442 incident genital wart cases did not have a specific anatomic location recorded. Most people with an incident genital wart diagnosis (87.2%) did not have a recurrence during the observation period. CONCLUSIONS: Our study found that the incidence of genital warts was highest among persons aged 20 to 24 years using a unique method to identify the location of the wart. Information on incidence of genital warts before vaccine use provides baseline data that can be used to measure HPV vaccine impact.
Asunto(s)
Condiloma Acuminado/prevención & control , Papillomaviridae/inmunología , Enfermedades del Pene/prevención & control , Enfermedades Uretrales/prevención & control , Enfermedades del Cuello del Útero/prevención & control , Enfermedades Vaginales/prevención & control , Enfermedades de la Vulva/prevención & control , Adolescente , Adulto , California/epidemiología , Niño , Estudios de Cohortes , Condiloma Acuminado/clasificación , Condiloma Acuminado/epidemiología , Condiloma Acuminado/virología , Prestación Integrada de Atención de Salud , Femenino , Humanos , Incidencia , Masculino , Vacunas contra Papillomavirus , Enfermedades del Pene/clasificación , Enfermedades del Pene/virología , Enfermedades Virales de Transmisión Sexual/clasificación , Enfermedades Virales de Transmisión Sexual/epidemiología , Enfermedades Virales de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/virología , Enfermedades Uretrales/clasificación , Enfermedades Uretrales/virología , Enfermedades del Cuello del Útero/clasificación , Enfermedades del Cuello del Útero/virología , Vacunación , Enfermedades Vaginales/clasificación , Enfermedades Vaginales/virología , Enfermedades de la Vulva/clasificación , Enfermedades de la Vulva/virología , Adulto JovenRESUMEN
The 28th International Papillomavirus Conference, hosted by the University of Puerto Rico Comprehensive Cancer Center, attracted approximately 1500 participants from 75 countries. The purpose of the meeting was mainly to provide a forum for the exchange of new knowledge; the status of HPV research and its future direction and the impact of current strategies for the prevention and control of HPV burden and HPV-related conditions. The meeting program consisted of a clinical workshop and a public health workshop followed by the main conference program. The main conference featured five breakfast sessions, four plenary sessions and 22 satellite symposia. Over 800 posters, 167 oral presentations and 53 poster-oral presentations were presented. This article highlights the most important issues discussed in HPV, which will be of interest to those working in the field of HPV vaccines.
Asunto(s)
Papillomaviridae/genética , Papillomaviridae/inmunología , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/inmunología , Investigación Biomédica/tendencias , Femenino , Humanos , Papillomaviridae/patogenicidad , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/administración & dosificaciónRESUMEN
AIM: Achieving high human papillomavirus (HPV) vaccine coverage is important because cervical screening coverage is declining. As key decision makers, mothers' experiences of, and participation in, the cervical screening programme could affect vaccination consent. We investigate whether mother's screening history influences daughter's participation in the HPV vaccination programme. METHODS: Mothers' cervical screening records from the National Health Authority Information System were linked to the daughters' HPV vaccination records from the Child Health System in North West England by address. Odds ratios for daughter's vaccination were computed using Logistic Regression, adjusting for age, Primary Care Trust and vaccine cohort (AOR). RESULTS: Daughters in both the routine and catch up programmes were more likely to have initiated vaccination and completed the course if their mothers had attended screening. The association was strongest when mothers had attended within the last 5 years (AOR in routine group: 3.5 (95% confidence interval (CI) 3.1-4.0) for initiation and 2.2 (1.6-2.9) for retention). Mothers who had personally decided to cease screening were less likely to have vaccinated daughters than those who had ceased for medical indications. Daughters were more likely to have been vaccinated if their mothers had received an abnormal smear result. CONCLUSIONS: Daughter's HPV vaccination uptake was associated with mother's cervical screening attendance. Daughters of mothers who are not engaged with preventive services are less likely to be vaccinated and may be less likely to engage with screening. This makes mothers central to health interventions to promote both cervical screening and HPV vaccination.
Asunto(s)
Madres/psicología , Núcleo Familiar/psicología , Infecciones por Papillomavirus/inmunología , Vacunas contra Papillomavirus/inmunología , Adolescente , Adulto , Anciano , Niño , Inglaterra , Femenino , Humanos , Modelos Logísticos , Tamizaje Masivo/métodos , Tamizaje Masivo/psicología , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Programas Nacionales de Salud/estadística & datos numéricos , Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/administración & dosificación , Aceptación de la Atención de Salud/psicología , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/prevención & control , Neoplasias del Cuello Uterino/virología , Vacunación/métodos , Vacunación/psicología , Vacunación/estadística & datos numéricosRESUMEN
OBJECTIVE: To investigate the possible mechanism of local hyperthermia in the treatment of warts through detecting the differences in CD1a/CD83 of Langerhans cells (LCs) in émigrés from HPV-infected skin, as compared to normal skin. METHODS: Confocal microscopy were performed on Condyloma Accuminatum (CA)and normal skin; Freshly taken biopsies of CA and normal skin were subjected to surface heating at 37 degrees C, 42 degrees C and 45 degrees C respectively, for 30 mins. Flow cytometry was used to determine the CD1a/ CD83 changes of LCs in émigrés from CA and normal skin. RESULTS: By confocal microscopic observation, there were practically no CD1a+ LCs that expressed CD83 in the epidermis of both normal skin and CA. The proportions of CD1a+/CD83 LCs were significantly increased with increased temperatures in émigrés from both normal skin and CA. At each given temperature, the numbers of LCs in émigrés from CA were greater than those from normal skin. CONCLUSION: Local hyperthermia can promote migration and maturation of LCs in HPV-infected skin and accordingly stimulate the immune system to treat warts.
Asunto(s)
Hipertermia Inducida , Células de Langerhans/citología , Papillomaviridae/inmunología , Piel/inmunología , Piel/virología , Adulto , Movimiento Celular/inmunología , Femenino , Humanos , Técnicas In Vitro , Células de Langerhans/inmunología , Papillomaviridae/patogenicidad , Adulto JovenRESUMEN
INTRODUCTION: External genital warts (EGWs) are sexually transmitted benign epidermal growths caused by the human papillomavirus (HPV), on the anogenital areas of both females and males. About 50% to 60% of sexually active women aged 18 to 49 years have been exposed to HPV infection, but only 10% to 15% will have genital warts. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for external genital warts? What are the effects of interventions to prevent transmission of external genital warts? We searched: Medline, Embase, The Cochrane Library, and other important databases up to December 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 55 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bi- and trichloroacetic acid; condoms; cryotherapy; electrosurgery; imiquimod; intralesional, topical, or systemic interferons; laser surgery; podophyllin; podophyllotoxin; surgical excision; and vaccines.
Asunto(s)
Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Condiloma Acuminado/tratamiento farmacológico , Método Doble Ciego , Humanos , Papillomaviridae/inmunología , Infecciones por Papillomavirus/tratamiento farmacológico , Vacunas contra Papillomavirus/inmunología , Podofilino/uso terapéuticoRESUMEN
La relación entre los virus papilomas humanos (VPH) de tipo mucoso (VPH-muc) y el carcinoma de cérvix o los carcinomas espinocelulares (CE) de la región ano-genital es cada vez más evidente. Sin embargo, la relación del VPH con el resto de los CE cutáneos es más controvertida. Recientes publicaciones relacionan los VPH tipo epidermodisplasia verruciforme (VPH-EV) con los CE cutáneos extra-genitales, sobre todo en los pacientes inmunodeprimidos, aunque también en los inmunocompetentes. Los VPH-muc también se podrían relacionar con algunas enfermedades de Bowen y determinados CE: dedos de manos, mucosa oro-faríngea, etc. Revisamos los posibles mecanismos oncogénicos de los VPH-muc y los VPH-EV. La mayoría de los CE podrían explicarse por la acción conjunta de los VPH, la inmunodepresión y los efectos oncogénicos e inmunosupresores de las radiaciones ultravioleta. Los VPH podrían implicar un peor pronóstico de los CE, con más posibilidades de producir metástasis, entre otras implicaciones en la práctica clínica
The relationship between mucosal human papillomavirus (HPV) and cervical carcinoma or anogenital squamous cell carcinoma (SCC) is becoming increasingly evident, whereas a link between HPV and other cutaneous SCCs is less clear. Recent studies have reported links between epidermodysplasia-verruciformis-associated HPV and extragenital cutaneous SCC, particularly in immunosuppressed patients, although immunocompetent patients have also been affected. Mucosal HPV could also be linked to some types of Bowen disease and certain SCCs of the fingers, oropharyngeal mucosa, etc. We review the possible oncogenic mechanisms involving mucosal HPV and epidermodysplasia-verruciformis-associated HPV. Most SCCs could be explained by the combined action of HPV, immunosuppression, and the oncogenic and immunosuppressive effect of UV radiation. HPV might be associated with worse prognosis of SCC, with implications for clinical practice including greater risk of metastasis
Asunto(s)
Masculino , Femenino , Humanos , Carcinoma/complicaciones , Carcinoma/diagnóstico , Epidermodisplasia Verruciforme/complicaciones , Epidermodisplasia Verruciforme/diagnóstico , Epidermodisplasia Verruciforme/complicaciones , Inmunosupresores/uso terapéutico , Terapia PUVA , Papillomaviridae/patogenicidad , Papillomaviridae/inmunología , Papillomaviridae/patogenicidad , Enfermedad de Bowen/complicaciones , Verrugas/complicaciones , Retinoblastoma/complicaciones , Retinoblastoma/diagnósticoRESUMEN
Infection with human papillomavirus (HPV) is the primary cause of cervical cancer, other anogenital cancers, genital warts, and recurrent respiratory papillomatosis. Clinical studies have demonstrated that a prophylactic HPV vaccine can prevent infection, genital warts, and the precancerous lesions that lead to cervical cancer. Given the absence of data on the long-term effectiveness of HPV vaccination, a number of mathematical models have been developed to provide insight to policy makers by projecting the long-term epidemiologic and economic consequences of vaccination and evaluate alternative vaccination policies. This paper reviews the state of these models. Three types of HPV mathematical models have been reported in the literature: cohort, population dynamic, and hybrid. All have demonstrated that vaccination can significantly reduce the incidence of cervical cancer in the long term. However, only the cohort and hybrid models have evaluated the cost-effectiveness of vaccination strategies for preventing cervical cancer. These models have generally shown that vaccinating females can be cost-effective. None has accounted for the potential benefits of vaccinating the population to reduce the burden of recurrent respiratory papillomatosis and cancers of the vagina, vulva, anus, penis, and head/neck. Given that only the population dynamic model can account for both the direct and indirect (i.e., herd immunity effects) benefits of vaccination in the population, future research should focus on further development of dynamic models by expanding the range of epidemiologic outcomes tracked and including the ability to assess the cost-effectiveness of alternative vaccination policies.
Asunto(s)
Programas de Inmunización/economía , Modelos Econométricos , Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/administración & dosificación , Análisis Costo-Beneficio , Femenino , Política de Salud , Humanos , Infecciones por Papillomavirus/economía , Infecciones por Papillomavirus/epidemiología , Vacunas contra Papillomavirus/economía , Años de Vida Ajustados por Calidad de VidaRESUMEN
Multivalent prophylactic human papillomavirus (HPV) vaccines currently in the late stages of clinical testing are safe, immunogenic, and efficacious; and phase 3 tests of a quadrivalent vaccine show that it is 100% effective at preventing HPV types 16 and 18-associated cervical intraepithelial neoplasia grades 2 and 3, adenocarcinoma in situ, and cervical cancer through 2 years of postvaccination follow-up. These vaccines promise to reduce the burden of HPV-related disease. Realizing the full benefit of these vaccines will require a vaccination program that addresses the needs and concerns of healthcare providers, parents, and young adolescent patients who will be involved in the vaccine decisionmaking process. Osteopathic physicians, by virtue of their dedication to holistic care, are in an optimal position to play a key role in facilitating acceptance of these vaccines among potential vaccinees and their parents and guardians.
Asunto(s)
Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus , Aceptación de la Atención de Salud , Vacunas Virales , Adolescente , Adulto , Actitud del Personal de Salud , Costos de los Medicamentos , Femenino , Conocimientos, Actitudes y Práctica en Salud , Humanos , Masculino , Vacunas Virales/economíaRESUMEN
The human papillomavirus 16 (HPV16) E7 oncoprotein can be considered a "tumor-specific antigen", and therefore it represents a promising target for a therapeutic vaccine against HPV-associated tumors. Efficient production of E7 protein with a plant-based transient expression system has been already described and it was demonstrated that E7-containing crude plant extracts confer partial protection against tumor challenge in a mouse model system. Before adopting the plant-based system as a cost-effective method for the production of an E7-based anti-cancer vaccine, some aspects, such as the oncoprotein yield, need further investigation. In the present study, we report the transient expression, mediated by a potato virus X (PVX)-derived vector, of the E7 protein targeted to the secretory system of Nicotiana benthamiana plants by using a plant-derived signal sequence. Targeting the antigen to the secretory pathway enhanced the E7 protein expression levels about five-fold. Mice immunized by s.c. administration with crude foliar extracts containing E7 showed strong stimulation of cell-mediated immune response after five boosters, as detected by ELISPOT. After challenging with the E7-expressing C3 tumor cells, tumor growth was completely inhibited in 80% of the vaccinated animals and a drastic reduction of tumor burden was observed in the remaining tumor-affected mice. These data demonstrate that, by enhancing E7 yield, it is possible to improve the anti-cancer activity of the plant-based experimental vaccine and open the way for a large-scale production of the E7 protein which could be purified or used as in planta formulation, also suitable for oral therapeutic vaccination.
Asunto(s)
Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/farmacología , Nicotiana/inmunología , Proteínas Oncogénicas Virales/inmunología , Papillomaviridae/inmunología , Vacunas Virales/inmunología , Vacunas Virales/farmacología , Animales , Antígenos Virales/inmunología , Western Blotting , ADN de Plantas/genética , ADN de Plantas/inmunología , Ensayo de Inmunoadsorción Enzimática , Espacio Extracelular/metabolismo , Femenino , Inmunización , Immunoblotting , Interferón gamma/metabolismo , Ratones , Ratones Endogámicos C57BL , Proteínas Oncogénicas Virales/genética , Papillomaviridae/genética , Proteínas E7 de Papillomavirus , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Linfocitos T/inmunología , Nicotiana/químicaRESUMEN
As cervical cancer is causally associated with 14 high-risk types of human papillomavirus (HPV), a successful HPV vaccine will have a major impact on this disease. Although some persistent HPV infections progress to cervical cancer, host immunity is generally able to clear most HPV infections. Both cell-mediated and antibody responses have been implicated in influencing the susceptibility, persistence or clearance of genital HPV infection. There have been two clinical trials that show that vaccines based on virus-like particles (VLPs) made from the major capsid protein, L1, are able to type specifically protect against cervical intra-epithelial neoplasia and infection. However, there is no evidence that even a mixed VLP vaccine will protect against types not included in the vaccine, and a major challenge that remains is how to engineer protection across a broader spectrum of viruses. Strategies for production of HPV vaccines using different vaccine vectors and different production systems are also reviewed.
Asunto(s)
Papillomaviridae/inmunología , Infecciones por Papillomavirus/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Vacunas Virales/uso terapéutico , Anticuerpos Antivirales/inmunología , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/uso terapéutico , Citocinas/inmunología , Femenino , Seropositividad para VIH/inmunología , Humanos , Inmunidad Celular/inmunología , Infecciones por Papillomavirus/inmunología , Fitoterapia/métodos , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/virologíaRESUMEN
Gynaecological malignancies, excluding breast cancer, cause approximately 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human papillomavirus (HPV) xenoantigens are readily recognised by the immune system, and their targeting has shown great promise in preclinical models of therapeutic vaccination and in clinical studies of preventative vaccination. A growing body of evidence indicates that ovarian cancer is also immunogenic and can thus be targeted through immunotherapy. This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment.
Asunto(s)
Traslado Adoptivo , Antígenos de Neoplasias/inmunología , Vacunas contra el Cáncer/uso terapéutico , Neoplasias de los Genitales Femeninos/terapia , Inmunoterapia , Neoplasias Ováricas/terapia , Papillomaviridae/inmunología , Neoplasias del Cuello Uterino/terapia , Vacunas Virales/uso terapéutico , Animales , Antígenos Heterófilos/inmunología , Ensayos Clínicos como Asunto , Citocinas , Evaluación Preclínica de Medicamentos , Femenino , Neoplasias de los Genitales Femeninos/inmunología , Neoplasias de los Genitales Femeninos/prevención & control , Humanos , Inmunoterapia/métodos , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/trasplante , Neoplasias Ováricas/inmunología , Neoplasias Ováricas/prevención & control , Linfocitos T Reguladores , Neoplasias del Cuello Uterino/inmunología , Neoplasias del Cuello Uterino/prevención & control , Vacunas Atenuadas/uso terapéuticoRESUMEN
Cervical cancer is linked to infection with human papillomaviruses (HPV) and is the third most common cancer among women worldwide. There is a strong demand for the development of an HPV preventive vaccine. Transgenic plants expressing the HPV major capsid protein L1 could be a system to produce virus-like particles for prophylactic vaccination or could even be used as edible vaccines to induce an L1-specific prophylactic immune response. Here, we describe the generation of transgenic tobacco and potato plants carrying the HPV type 16 major structural gene L1 under the control of the cauliflower mosaic virus 35S promoter. All attempts to express either the original, unmodified L1 gene or an L1 gene with a codon usage optimized for expression in plants failed. Surprisingly, small amounts of the protein were detected using an L1 gene optimized for expression in human cells. However, Northern blot analysis revealed that most of the L1 transcripts were degraded. Introduction of the translational enhancer Omega derived from the tobacco mosaic virus strongly increased transcript stability and resulted in accumulation of L1 protein to approximately 0.5 to 0.2% of total soluble protein in transgenic tobacco and potato plants, respectively. The plant-derived L1 protein displayed conformation-specific epitopes and assembled into virus-like particles. Furthermore, we did not find any indications of protein modification of the L1 protein produced in plants. Plant-derived L1 was as immunogenic as L1 expressed in baculovirus-infected insect cells. Feeding of tubers from transgenic potatoes to mice induced an anti-L1 antibody response in 3 out of 24 mice, although this response was only transient in two of the mice. Our data, however, indicate that an anti-L1 response was primed in about half of the 24 animals.